**Friday, June 7**

| Time          | Session 1 – Malignancy Diagnosis and Treatment - Genomic Approaches | Moderator: Tom O’Hare, PhD  
Division of Hematology & Hematological Malignancies, University of Utah |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00–9:45 AM</td>
<td>Jeff Tyner, PhD</td>
<td>Functional genomics as a tool to drive personalized medicine</td>
</tr>
<tr>
<td></td>
<td>Oregon Health Sciences Center</td>
<td></td>
</tr>
<tr>
<td>9:45–10:20 AM</td>
<td>Gabor Marth, DSc</td>
<td>Understanding tumor evolution at sub clonal resolution</td>
</tr>
<tr>
<td></td>
<td>Human Genetics, University of Utah</td>
<td></td>
</tr>
<tr>
<td>10:20–11:05 AM</td>
<td>Iłaria Iacobucci, PhD</td>
<td>Genomic subtyping and therapeutic targeting of acute erythroleukemia</td>
</tr>
<tr>
<td></td>
<td>St. Jude’s Children’s Hospital</td>
<td></td>
</tr>
<tr>
<td>11:05–11:30 AM</td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>

**Session 2 – Innate Immunity and Mitochondria Effects on Myeloid Malignancy Mechanisms and Treatments**  
Moderator: Vedran Radojcic, MD  
Division of Hematology & Hematological Malignancies, University of Utah

| Time          | Session 2 – Innate Immunity and Mitochondria Effects on Myeloid Malignancy Mechanisms and Treatments | Moderator: Vedran Radojcic, MD  
Division of Hematology & Hematological Malignancies, University of Utah |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30–12:15 PM</td>
<td>Dan Starczynowski, PhD</td>
<td>Spliceosome gene mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies</td>
</tr>
<tr>
<td></td>
<td>Cincinnati Children’s Hospital</td>
<td></td>
</tr>
<tr>
<td>12:15–12:50 PM</td>
<td>Tom O’Hare, PhD</td>
<td>Target shooting in the Wasatch: Taking down compound mutants in Ph+ leukemia and stalking SIRT5 in AML</td>
</tr>
<tr>
<td></td>
<td>Hematology, University of Utah</td>
<td></td>
</tr>
<tr>
<td>12:50–1:35 PM</td>
<td>Brian Betts, MD</td>
<td>Dendritic cell ER stress response as a therapeutic target to prevent GVHD</td>
</tr>
<tr>
<td></td>
<td>Hematology, Oncology &amp; Transplantation, University of Minnesota</td>
<td></td>
</tr>
<tr>
<td>1:35–2:30 PM</td>
<td>Lunch break, hotel check-in, free time</td>
<td></td>
</tr>
</tbody>
</table>

**Session 3 – Novel Therapies for “-omas”**  
Moderator: Ami Patel, MD  
Division of Hematology & Hematological Malignancies, University of Utah

| Time          | Session 3 – Novel Therapies for “-omas” | Moderator: Ami Patel, MD  
Division of Hematology & Hematological Malignancies, University of Utah |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2:30–3:15 PM</td>
<td>Loretta Nastoupil, MD</td>
<td>Evolving treatment strategies in follicular lymphoma</td>
</tr>
<tr>
<td></td>
<td>MD Anderson Cancer Center</td>
<td></td>
</tr>
<tr>
<td>3:15–3:50 PM</td>
<td>Sabarinath Radhakrishnan, MD</td>
<td>CD229 CAR T cell therapy for multiple myeloma</td>
</tr>
<tr>
<td></td>
<td>Hematology, University of Utah</td>
<td></td>
</tr>
<tr>
<td>3:50 PM</td>
<td>Hiking, socializing</td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td>Dinner and socializing</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session 4 – Hematopoiesis</td>
<td>Session 5 – Beyond Genomics: Novel Molecular Mechanisms of Tumor Cell Survival and Therapeutics</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:30–9:15 AM</td>
<td>Siddharta Jaiswal, MD, PhD</td>
<td>Clonal hematopoiesis in human aging and disease</td>
</tr>
<tr>
<td>9:15–9:50 AM</td>
<td>Jan Christian, PhD</td>
<td>BMP7 functions predominantly as a heterodimer throughout mammalian embryogenesis: implications for human syndromes caused by mutations in Bmp4 or Bmp7</td>
</tr>
<tr>
<td>9:50–10:25 AM</td>
<td>Josef Prchal, MD</td>
<td>Hypoxia, Erythropoiesis and High Altitude Evolutionary Adaptation</td>
</tr>
<tr>
<td>10:25–10:45 AM</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>10:45–11:30 AM</td>
<td>Hans-Guido Wendel, MD</td>
<td>Exploring new cancer targets</td>
</tr>
<tr>
<td>11:30–12:05 AM</td>
<td>Tracy George, MD</td>
<td>Potential new therapeutic targets for mastocytosis</td>
</tr>
<tr>
<td>12:05–12:40 PM</td>
<td>Minna Roh-Johnson, PhD</td>
<td>Macrophage-dependent cytoplasmic transfer during cell invasion</td>
</tr>
<tr>
<td>12:40 PM</td>
<td>Lunch and departure</td>
<td></td>
</tr>
</tbody>
</table>